ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/pibrentasvir

First Posted Date: 2017-03-03

Last Posted Date: 2019-03-04

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT03069365

Locations: 🇺🇸
Northwest Louisiana Nephrology /ID# 160652, Shreveport, Louisiana, United States
🇩🇪
Univ Johannes Gutenberg /ID# 160828, Mainz, Germany
🇵🇷
School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 160755, San Juan, Puerto Rico

and more 35 locations

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir + Pibrentasvir Pediatric Formulation
Drug: Glecaprevir/Pibrentasvir Adult Formulation

First Posted Date: 2017-03-01

Last Posted Date: 2023-05-09

Lead Sponsor: AbbVie

Target Recruit Count: 129

Registration Number: NCT03067129

Locations: 🇺🇸
Boston Childrens Hospital /ID# 157988, Boston, Massachusetts, United States
🇺🇸
Indiana University /ID# 158001, Indianapolis, Indiana, United States
🇧🇪
UZ Leuven /ID# 162174, Leuven, Belgium

and more 35 locations

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Topotecan
Drug: Rovalpituzumab tesirine
Drug: Dexamethasone

First Posted Date: 2017-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 444

Registration Number: NCT03061812

Locations: 🇺🇸
Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States
🇺🇸
Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States
🇺🇸
Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States

and more 192 locations

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2017-02-15

Last Posted Date: 2019-03-14

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT03053180

Locations: 🇷🇺
KOGBUZ Kirovsk Infect Hosp, Kirov, Russian Federation
🇷🇺
South-Ural State Med. Academy, Chelyabinsk, Russian Federation
🇷🇺
Specialized Clinical Infectiou, Krasnodar, Russian Federation

and more 4 locations

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: risankizumab

First Posted Date: 2017-02-09

Last Posted Date: 2024-12-11

Lead Sponsor: AbbVie

Target Recruit Count: 2170

Registration Number: NCT03047395

Locations: 🇺🇸
Total Skin and Beauty Dermatology Center /ID# 154000, Birmingham, Alabama, United States
🇺🇸
Great Lakes Research Group - Bay City /ID# 153998, Bay City, Michigan, United States
🇺🇸
Oregon Medical Research Center /ID# 154003, Portland, Oregon, United States

and more 230 locations

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: SC-006
Drug: ABBV-181

First Posted Date: 2017-01-30

Last Posted Date: 2020-02-20

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT03035279

Locations: 🇺🇸
University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States
🇺🇸
Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States

and more 6 locations

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Phase 3

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Placebo for dexamethasone
Drug: Rovalpituzumab tesirine
Drug: Placebo for rovalpituzumab tesirine
Drug: Dexamethasone

First Posted Date: 2017-01-26

Last Posted Date: 2021-07-29

Lead Sponsor: AbbVie

Target Recruit Count: 748

Registration Number: NCT03033511

Locations: 🇺🇸
Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas, United States
🇺🇸
LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California, United States
🇺🇸
Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania, United States

and more 305 locations

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: ABBV-951

First Posted Date: 2017-01-26

Last Posted Date: 2024-11-11

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT03033498

Locations: 🇺🇸
Glendale Adventist Medical Ctr /ID# 166512, Glendale, California, United States
🇺🇸
Acpru /Id# 154976, Grayslake, Illinois, United States
🇺🇸
Parexel Baltimore /ID# 169255, Baltimore, Maryland, United States

and more 4 locations

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Rovalpituzumab tesirine

First Posted Date: 2017-01-20

Last Posted Date: 2020-07-17

Lead Sponsor: AbbVie

Target Recruit Count: 42

Registration Number: NCT03026166

Locations: 🇺🇸
University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States
🇺🇸
University of Chicago /ID# 161006, Chicago, Illinois, United States
🇪🇸
Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain

and more 32 locations

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: risankizumab

First Posted Date: 2017-01-16

Last Posted Date: 2021-11-18

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT03022045

Locations: 🇯🇵
Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan
🇯🇵
Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
🇯🇵
Tokyo Medical University Hosp, Shinjuku-ku, Tokyo, Japan

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy